On Monday 3 April, the European Medicines Agency (EMA) highlighted that the adjustment of fees for applications made by applicants for, or holders of, European market authorisations for pharmaceutical products, with the exception of fees charged for pharmacovigilance procedures, came into force on 1 April.
These adjustments follow the adoption by the European Commission on Wednesday 29 March of Regulation EU/2023/699 on the adjustment of fees payable to the European Medicines Agency on...